Affected children are born with café-au-lait spots and sometimes Lisch nodules. During adolescence and young adulthood, more than 19% of affected individuals with NF1 develop cutaneous neurofibromas ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.